The optimal interval before receiving SARS-COV-2 vaccination for patients who have received Anti-CD 20 monoclonal antibodies

References

• Vijenthira A, Gong I, Betschel SD, et al. Vaccine response following anti-CD20 therapy: a systematic review and meta-analysis of 905 patients. Blood Adv. 2021;5(12):2624–2643. DOI:10.1182/bloodadvances.2021004629
   PubMed Web of Science ®Google Scholar
• Achiron A, Mandel M, Dreyer-Alster S, et al. Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies. Ther Adv Neurol Disord. 2021;14:17562864211012835.
   Web of Science ®Google Scholar
• Furer V, Eviatar T, Zisman D, et al. Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study. Ann Rheum Dis. 2021;80(10):1330–1338. DOI:10.1136/annrheumdis-2021-220647
   PubMed Web of Science ®Google Scholar
• Herishanu Y, Avivi I, Aharon A, et al. Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia. Blood. 2021;137(23):3165–3173. DOI:10.1182/blood.2021011568
   PubMed Web of Science ®Google Scholar
• Sattler A, Schrezenmeier E, Weber UA, et al. Impaired humoral and cellular immunity after SARS-CoV-2 BNT162b2 (tozinameran) prime-boost vaccination in kidney transplant recipients. J Clin Invest. 2021;131(14). DOI:10.1172/JCI150175.
   Web of Science ®Google Scholar
• Madelon N, Lauper K, Breville G, et al. Robust T cell responses in anti-CD20 treated patients following COVID-19 vaccination: a prospective cohort study. Clin Infect Dis. 2021;75(1):e1037–1045. DOI:10.1093/cid/ciab954
   Web of Science ®Google Scholar
• Baker D, Roberts CAK, Pryce G, et al. COVID-19 vaccine-readiness for anti-CD20-depleting therapy in autoimmune diseases. Clin Exp Immunol. 2020;202(2):149–161. DOI:10.1111/cei.13495
   PubMed Web of Science ®Google Scholar
• Avivi I, Luttwak E, Saiag E, et al. Bnt162b2 mRNA COVID-19 vaccine booster induces seroconversion in patients with B-cell non-Hodgkin lymphoma who failed to respond to two prior vaccine doses. Br J Haematol. 2022;196(6):1329–1333. DOI:10.1111/bjh.18029
   PubMed Web of Science ®Google Scholar
• Bitoun S, Henry J, Desjardins D, et al. Rituximab impairs b cell response but not t cell response to COVID-19 vaccine in autoimmune diseases. Arthritis Rheumatol. 2021;74(6):927–933. DOI:10.1002/art.42058
   Web of Science ®Google Scholar
• Bonelli M, Mrak D, Tobudic S, et al. Additional heterologous versus homologous booster vaccination in immunosuppressed patients without SARS-CoV-2 antibody seroconversion after primary mRNA vaccination: a randomised controlled trial. Ann Rheum Dis. 2022;81(5):687–694. DOI:10.1136/annrheumdis-2021-221558
   PubMed Web of Science ®Google Scholar
• Brill L, Raposo C., Rechtman A. et al. SARS-CoV-2 third vaccine immune response in MS patients treated with ocrelizumab. medRxiv. 2022;2022.01.26.22269876. https://doi.org/10.1101/2022.01.26.22269876
   Google Scholar
• Buchwinkler L, Solagna CA, Messner J, et al. Antibody response to mRNA vaccines against SARS-CoV-2 with chronic kidney disease, hemodialysis, and after kidney transplantation. J Clin Med. 2022;11(1):148. DOI:10.3390/jcm11010148
   Web of Science ®Google Scholar
• Carruthers JE, Wells J, Gupta A, et al. Response to vaccination against sars-COV-2 in patients with antineutrophil cytoplasmic antibody-associated vasculitis with renal involvement. Front Med (Lausanne). 2022;8. DOI:10.3389/fmed.2021.817845.
   PubMed Web of Science ®Google Scholar
• Cohen D, Hazut Krauthammer S, Cohen YC, et al. Correlation between BNT162b2 mRNA Covid-19 vaccine-associated hypermetabolic lymphadenopathy and humoral immunity in patients with hematologic malignancy. Eur J Nucl Med Mol Imaging. 2021;48(11):3540–3549. DOI:10.1007/s00259-021-05389-x
   PubMed Web of Science ®Google Scholar
• Diefenbach C, Caro J., Koide A. et al. Impaired humoral immunity to sars-cov-2 vaccination in non-Hodgkin lymphoma and cll patients. medRxiv. 2021;2021.06.02.21257804. https://doi.org/10.1101/2021.06.02.21257804
   Google Scholar
• Firinu D, Perra A., Campagna M. et al. Evaluation of antibody response to BNT162b2 mRNA COVID-19 vaccine in patients affected by immune-mediated inflammatory diseases up to 5 months after vaccination. Clin Exp Med. 2022;22: 477–485. https://doi.org/10.1007/s10238-021-00771-3
   PubMed Web of Science ®Google Scholar
• Gadani SP, Reyes-Mantilla M., Jank L. et al. Discordant humoral and T cell immune responses to SARS-CoV-2 vaccination in people with multiple sclerosis on anti-CD20 therapy. medRxiv. 2021;2021.08.23.21262472. https://doi.org/10.1101/2021.08.23.21262472
   Google Scholar
• Gurion R, Rozovski U, Itchaki G, et al. Humoral serologic response to the BNT162b2 vaccine is abrogated in lymphoma patients within the first 12 months following treatment with anti-CD2O antibodies. Haematologica. 2021;107(3):715–720. DOI:10.3324/haematol.2021.279216
   Web of Science ®Google Scholar
• Haidar G, Agha M, Bilderback A, et al. Prospective evaluation of COVID-19 vaccine responses across a broad spectrum of immunocompromising conditions: the COVICS study. Clin Infect Dis. 2022;75(1):e630–644. DOI:10.1093/cid/ciac103
   PubMed Web of Science ®Google Scholar
• Jinich S, Schultz K, Jannat‐khah D, et al. B cell reconstitution is strongly associated with covid-19 vaccine responsiveness in rheumatic disease patients who received treatment with rituximab. Arthritis Rheumatol. 2021;74(5):776–782. DOI:10.1002/art.42034
   Web of Science ®Google Scholar
• König M, Lorentzen ÅR, Torgauten HM, et al. Humoral immunity to SARS-CoV-2 mRNA vaccination in multiple sclerosis: the relevance of time since last rituximab infusion and first experience from sporadic revaccinations. J Neurol Neurosurg Psychiatry. jnnp-2021. 2021;327612. DOI:10.1136/jnnp-2021-327612.
   Web of Science ®Google Scholar
• Kornek B, Leutmezer F, Rommer PS, et al. B cell depletion and sars-COV-2 vaccine responses in neuroimmunologic patients. Ann Neurol. 2022;91(3):342–352. DOI:10.1002/ana.26309
   PubMed Web of Science ®Google Scholar
• Kornek B, Leutmezer F., Rommer P.S. et al. SSRN-Distinct patterns of humoral and cellular immune responses following SARS-CoV-2.Pdf. 2022. Vol. 91. pp.342–352. DOI:10.1002/ana.26309.
   Google Scholar
• Krasselt M, Wagner U, Nguyen P, et al. Humoral and cellular response to covid-19 vaccination in patients with autoimmune inflammatory rheumatic diseases under real-life conditions. Rheumatology (Oxford). 2022;61(SI2):SI180–188. DOI:10.1093/rheumatology/keac089
   PubMed Web of Science ®Google Scholar
• Lim SH, Campbell N., Stuart B., et al. Humoral and cellular responses to SARS-CoV-2 vaccination in patients with lymphoid malignancies. medRxiv. 2021;2021.12.08.21266760. https://doi.org/10.1101/2021.12.08.21266760
   Google Scholar
• Marty PK, Van Keulen VP, Erskine CL, et al. Antigen specific humoral and cellular immunity following sars-cov-2 vaccination in anca-associated vasculitis patients receiving b-cell depleting therapy. Front Immunol. 2022;13:834981.
   PubMed Web of Science ®Google Scholar
• Moor MB, Suter-Riniker F, Horn MP, et al. Humoral and cellular responses to mRNA vaccines against SARS-CoV-2 in patients with a history of CD20 B-cell-depleting therapy (RituxiVac): an investigator-initiated, single-centre, open-label study. Lancet Rheumatol. 2021;3(11):e789–797. DOI:10.1016/S2665-9913(21)00251-4
   PubMedGoogle Scholar
• Novak F, Nilsson AC, Nielsen C, et al. Humoral immune response following SARS-CoV-2 mRNA vaccination concomitant to anti-CD20 therapy in multiple sclerosis. Mult Scler Relat Disord. 2021;56:103251.
   PubMed Web of Science ®Google Scholar
• Perry C, Luttwak E, Balaban R, et al. Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with B-cell non-Hodgkin lymphoma. Blood Adv. 2021;5(16):3053–3061. DOI:10.1182/bloodadvances.2021005094
   PubMed Web of Science ®Google Scholar
• Schulz E, Hodl I., and Forstner, P. et al. CD19+IgD+CD27− naïve B Cells as predictors of humoral response to COVID-19 mRNA vaccination in immunocompromised patients. medRxiv. 2021;2021.08.11.21261898. https://doi.org/10.1101/2021.08.11.21261898
   Google Scholar
• Stefanski AL, Rincon‐arevalo H., Schrezenmeier E. et al. B cell numbers predict humoral and cellular response upon SARS-CoV-2 vaccination among patients treated with rituximab. Arthritis Rheumatol. 2021;74:934–947. https://doi.org/10.1002/art.42060
   Web of Science ®Google Scholar
• Tanguay M, Boutin M, Laumaea A, et al. B-cell cytopenia and time to last B-cell-depleting therapy predict response to SARS-COV-2 vaccines in patients with lymphoproliferative disorders. Vaccine. 2022;40(9):1203–1207. DOI:10.1016/j.vaccine.2022.01.040
   PubMed Web of Science ®Google Scholar
• Tvito A, Ronson A, Ghosheh R, et al. Anti-CD20 monoclonal antibodies inhibit seropositive response to Covid-19 vaccination in non-Hodgkin lymphoma patients within 6 months after treatment. Exp Hematol. 2022;107:20–23.
   PubMed Web of Science ®Google Scholar